QQQ0.32%

Trending

KAIO27.98%

home Symbol CORTnews

CORT
Corcept Therapeutics Inc

4,470

Mkt Cap

$7.46B

Volume

775,040.00

52W High

$91.00

52W Low

$28.66

PE Ratio

198.54

CORT Fundamentals

Price

$69.49

Prev Close

$68.38

Open

$68.57

50D MA

$48.03

Beta

1.37

Avg. Volume

1.06M

EPS (Annual)

$0.8182

P/B

11.69

Rev/Employee

$1.04M

$3,809.50

Info

News

all

press releases

Corcept Presents New Data at ASCO 2026: Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival...

Business Wire

More News

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.

Zacks

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept said it will resubmit the new drug application in the coming weeks after positive talks with the U.S. Food and Drug Administration.

Stocktwits

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushings Syndrome

Business Wire

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.

Zacks

Corcept Therapeutics (NASDAQ:CORT) Upgraded by Zacks Research to Hold Rating

Zacks Research upgraded shares of Corcept Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday...

MarketBeat

HC Wainwright Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for Corcept Therapeutics in a research...

MarketBeat

Corcept Therapeutics Incorporated $CORT Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 70.8% in the 4th quarter, according to its most...

MarketBeat

Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9% - Time to Buy?

Corcept Therapeutics (NASDAQ:CORT) Trading 7.9% Higher - Time to Buy...

MarketBeat

...